Show simple item record

dc.contributor.authorHoyle, M
dc.contributor.authorCrathorne, Louise
dc.contributor.authorPeters, J
dc.contributor.authorJones-Hughes, T
dc.contributor.authorCooper, Chris
dc.contributor.authorNapier, Mark
dc.contributor.authorTappenden, P
dc.contributor.authorHyde, C
dc.date.accessioned2013-09-30T08:48:07Z
dc.date.issued2013-04
dc.description.abstractColorectal cancer is the third most commonly diagnosed cancer in the UK after breast and lung cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy. Recently, targeted agents have become available including anti-epidermal growth factor receptor (EGFR) agents, for example cetuximab and panitumumab, and anti-vascular endothelial growth factor (VEGF) receptor agents, for example bevacizumab.en_GB
dc.identifier.citationVol. 17, Issue 14, pp. 1 - 237en_GB
dc.identifier.doi10.3310/hta17140
dc.identifier.urihttp://hdl.handle.net/10871/13703
dc.language.isoenen_GB
dc.publisherNIHR Health Technology Assessment Programmeen_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/23547747en_GB
dc.subjectAngiogenesis Inhibitorsen_GB
dc.subjectAnimalsen_GB
dc.subjectAntibodies, Monoclonalen_GB
dc.subjectAntibodies, Monoclonal, Humanizeden_GB
dc.subjectAntineoplastic Agentsen_GB
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_GB
dc.subjectClinical Protocolsen_GB
dc.subjectClinical Trials as Topicen_GB
dc.subjectColorectal Neoplasmsen_GB
dc.subjectCost-Benefit Analysisen_GB
dc.subjectDisease-Free Survivalen_GB
dc.subjectGreat Britainen_GB
dc.subjectHumansen_GB
dc.subjectModels, Economicen_GB
dc.subjectQuality-Adjusted Life Yearsen_GB
dc.titleThe clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic modelen_GB
dc.typeArticleen_GB
dc.date.available2013-09-30T08:48:07Z
dc.identifier.issn1366-5278
exeter.place-of-publicationEngland
dc.identifier.journalHealth Technology Assessmenten_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record